Journal Article

GSI-2025-00509

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Carbon minibeam radiation therapy results in tumor growth delay in an osteosarcoma murine model

Bertho, A. ; Graeff, C.GSI* ; Ortiz, R. ; Giorgi, M. ; Schuy, C.GSI* ; Juchaux, M. ; Gilbert, C. ; Espenon, J. ; Oppermann, J.GSI* ; Sokol, O.GSI* ; Tinganelli, W.GSI* ; Prezado, Y. (Corresponding author)

2025
Springer Nature [London]

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/s41598-025-91872-6  doi:10.15120/GSI-2025-00509

Abstract: Despite remarkable advances, radiation therapy (RT) remains inefficient for some bulky tumors, radioresistant tumors, and certain pediatric tumors. Minibeam radiation therapy (MBRT) has emerged as a promising approach, reducing normal tissue toxicity while enhancing immune responses. Preclinical studies using X-rays and proton MBRT have demonstrated enhanced therapeutic index for aggressive tumor models. Combining MBRT's advantages of spatial dose fractionation with the physical and biological benefits of carbon ions could be a step further toward unleashing the full potential of MBRT. This study aims to perform the first in vivo study of local and systemic responses of a subcutaneous mouse osteosarcoma (metastatic) model to carbon MBRT (C-MBRT) versus conventional carbon ion therapy (CT). Irradiations were conducted at the GSI Helmholtz Centre in Germany using 180 MeV/u 12C ions beam. All irradiated animals received an average dose (20 Gy) and displayed a significant and similar tumor growth delay in addition to a decreased metastasis score compared to the non-irradiated group. In the C-MBRT group, 70% of the tumor volume received the valley dose, which is a very low dose of 1.5 Gy. The remaining 30% of the tumor received the peak dose of 105 Gy, resulting in an average dose of 20 Gy. These results suggest that C-MBRT triggered distinct mechanisms from CT and encourage further investigations to confirm the potential of C-MBRT for efficient treatment of radioresistant tumors.

Keyword(s): Animals (MeSH) ; Osteosarcoma: radiotherapy (MeSH) ; Osteosarcoma: pathology (MeSH) ; Mice (MeSH) ; Heavy Ion Radiotherapy: methods (MeSH) ; Disease Models, Animal (MeSH) ; Cell Line, Tumor (MeSH) ; Bone Neoplasms: radiotherapy (MeSH) ; Bone Neoplasms: pathology (MeSH) ; Carbon (MeSH) ; Tumor Burden: radiation effects (MeSH) ; Carbon ions ; Carbon minibeam radiation therapy (C-MBRT) ; Carbon therapy ; Minibeam radiation therapy ; Osteosarcoma ; Radioresistant tumor ; Carbon

Note: This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License

---

Contributing Institute(s):

1. Biophysik (BIO)
2. Collaboration FAIR: BIO (BIO@FAIR)

Research Program(s):

1. 633 - Life Sciences – Building Blocks of Life: Structure and Function (POF4-633) (POF4-633)
2. FAIR Phase-0 - FAIR Phase-0 Research Program (GSI-FAIR-Phase-0) (GSI-FAIR-Phase-0)
3. HITRIplus - Heavy Ion Therapy Research Integration plus (101008548) (101008548)
4. PROTONMBRT - Spatial fractionation of the dose in proton therapy: a novel therapeutic approach (817908) (817908)

Experiment(s):

1. SBio08_Prezado: Heavy Ion Spatial Fractionated Radiotherapy (POF3-315; HTM )

Appears in the scientific report 2025

---

Database coverage:
; ; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Physical, Chemical and Earth Sciences ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection ; Zoological Record

---